title: Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas.
abstract: Annexin A2 and Cdc42 were identified by 2-dimensional electrophoresis (2-DE) and MALDI-TOF-MS between esophageal squamous cell carcinomas (ESCC) and corresponding normal esophagus mucosa in our previous study. To assess clinico-pathological pattern and Annexin A2 and Cdc42 status with respect to cell differentiation and lymphnode metastasis in patients with ESCC. The expression of Annexin A2 and Cdc42 in 22 pairs of fresh ESCC and matched tissues were detected by qRT-PCR and western blot, respectively. And it was further confirmed by immunohistochemistry with 175 pairs of formalin-fixed, paraffin-embedded ESCC. Results showed that Annexin A2 expression was significantly down-regulated, and Cdc42 was up-regulated in ESCC compared to matched control on both mRNA and protein level (P < 0.05), which was in accordance with our previous results on proteomics data. Additionally, Annexin A2 and Cdc42 expression was significantly correlated with lymphoid node metastasis (P < 0.05) and pathological differentiation (P < 0.05). Taken together, we proposed that the aberrant expression of Annexin A2 and Cdc42 played a role in carcinogenesis, differentiation and metastasis of ESCC, which implied its potential target for clinical biomarkers in differentiation and lymph node metastasis.
authors: Medical Research Center, The Affiliated Hospital, Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, People's Republic of China.
authors: Jun-Guo
authors: JG
authors: Feng
authors: Qing
authors: Q
authors: Liu
authors: Xu
authors: X
authors: Qin
authors: Yue-Hua
authors: YH
authors: Geng
authors: Shu-Tao
authors: ST
authors: Zheng
authors: Tao
authors: T
authors: Liu
authors: Ilyar
authors: I
authors: Sheyhidin
authors: Xiao-Mei
authors: XM
authors: Lu
references: Proteomics. 2010 Sep;10(18):3210-21
references: 20707004
references: Cell Motil Cytoskeleton. 2007 May;64(5):338-46
references: 17301947
references: Ann Oncol. 2010 Oct;21 Suppl 7:vii205-10
references: 20943616
references: Mol Biol Rep. 2011 Jun;38(5):3261-9
references: 21125333
references: Biomarkers. 2009 Aug;14(5):340-6
references: 19552569
references: Nat Clin Pract Gastroenterol Hepatol. 2008 Sep;5(9):517-26
references: 18679388
references: Mol Biol Rep. 2010 Oct;37(7):3207-16
references: 19842058
references: J Thorac Cardiovasc Surg. 1990 May;99(5):929-38
references: 2329832
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Am J Pathol. 2007 Mar;170(3):951-66
references: 17322380
references: Anticancer Res. 2001 Mar-Apr;21(2B):1339-45
references: 11396210
references: Semin Oncol. 2010 Jun;37(3):224-42
references: 20709207
references: Mass Spectrom Rev. 2010 Nov-Dec;29(6):945-61
references: 20945361
references: Cancer Res. 2006 Apr 1;66(7):3523-30
references: 16585176
references: Cancer Genomics Proteomics. 2010 Jul-Aug;7(4):181-9
references: 20656984
references: Eur J Gastroenterol Hepatol. 2010 Aug;22(8):917-25
references: 20520561
references: Clin Cancer Res. 2004 Jul 15;10(14):4799-805
references: 15269155
references: Mol Biol Rep. 2011 Jan;38(1):631-8
references: 20369385
references: J Pathol. 2006 Apr;208(5):673-85
references: 16450333
references: Histol Histopathol. 2005 Jul;20(3):673-80
references: 15944914
references: Cancer. 2001 Sep 15;92(6):1419-26
references: 11745218
references: Gut. 2009 Jan;58(1):127-43
references: 19091831